NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated August 1, 2026

Supplement × Prescription·Evidence index

Cyclosporine and Potassium: what the published research says

PubMed indexes 3 records that name Cyclosporine and Potassium together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.

Read this first

An evidence index, not guidance.

Every statement below is attributed to a named, dated, linked source.

This page lists published research relevant to Cyclosporine and Potassium. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.

The research

3 studies naming Cyclosporine and Potassium.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

Serum potassium concentrations in cyclosporine- and azathioprine-treated renal transplant patients.

Nephron · 1985 · PMID 3892345

Clinical TrialComparative StudyRandomized Controlled Trial50 participants

“Serum concentrations of electrolytes and renal function data in hyperkalemic and normokalemic transplant patients receiving cyclosporine were similar. These observations suggest an association between cyclosporine administration and hyperkalemia in renal transplant recipients.”

Foley et al. · From the abstract

Names both Cyclosporine and Potassium in its title.

Different effects of cyclosporine a and FK506 on potassium transport systems in MDCK cells.

Experimental nephrology · 2001 · PMID 11549851

Animal study

“Both CsA and FK506 showed acute toxicity in MDCK cells in vitro with the effects of FK506 being less pronounced. CsA and FK506 had different effects on the in vivo transport rates of the Na(+)/K(+)-ATPase and the Na(+)/K(+)/2Cl(-) cotransporter; CsA inhibited the activity of the Na(+)/K(+)-ATPase and the Na(+)/K(+)/2Cl(-) cotransporter whereas FK506 stimulated the activity of Na(+)/K(+)/2Cl(-) cotransporter. These effects were abolished by the application of aldosterone.”

Aker et al. · Authors' conclusion

Names both Cyclosporine and Potassium in its title.

Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity.

Kidney international · 2000 · PMID 11115079

Animal study

“Our findings indicate that both potassium and magnesium supplementations showed beneficial effects against CsA-induced hypertension and nephrotoxicity. The protective effect of magnesium clearly exceeded that of potassium. The greatest protection against CsA toxicity was achieved when potassium and magnesium were combined. We also provide evidence that the development of CsA-induced glomerular, tubular, and vascular lesions are associated with renal dopaminergic deficiency.”

Pere et al. · Authors' conclusion

Names both Cyclosporine and Potassium in its title.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Cyclosporine, Potassium, and several hundred other substances.

The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.